The FDA expects organizations to have full visibility and control over their processes

Free content from Dassault Systèmes BIOVIA

Expectations include: • Understanding products and processes in order to implement Quality by Design (QbD) into product development • Delivery of quality metrics for risk-based inspection schedules as proposed by a new quality metrics program • Shared responsibility for products manufactured by their Contract Manufacturing Organizations (CMOs) • Drive improvements in manufacturing technology, product quality and safety - reducing recalls and mitigating drug shortages

Sign up to download The FDA expects organizations to have full visibility and control over their processes

By clicking "Sign Up" you agree to our Privacy Policy and Terms of Use